About the Summit
After spending decades in the shadows, psychedelics have slowly reemerged as an effective treatment option for a wide variety of behavioral health issues including depression, anxiety, PTSD, chronic inflammation and addiction. With the cannabis legalization movement creeping towards maturity, American society has moved towards a more open-minded approach when it comes to this family of drugs that remain legally classified as a Schedule I substance under the Controlled Substances Act as the potential to provide relief to millions of afflicted people is an opportunity to large to ignore.
With a regulatory pathway already established, the next barrier is funding, but in order to drive greater investment, all interested parties must first understand the opportunity; from size and scope to models and applications.
Momentum’s Psychedelic Opportunity Summit has been designed to provide attendees with the scientific, medical, regulatory, economic, cultural and entrepreneurial knowledge need to determine an investment strategy. Whether you’re an investor, an insurance company, a pharmaceutical company, hospital system or entrepreneur, there is opportunity in the use of psychedelics to address a range of ailments including depression, anxiety, addiction, PTSD, chronic inflammation and alzheimers.
Attend this conference you will gain real world knowledge from industry veterans, experts, medical professionals and entrepreneurs including:
The Current State of Psychedelic Affairs, Research, Trials, and Conclusions
The Legal and Regulatory Environment for Psychedelics
Effectively Running Clinical Trials with a Psychedelic and Therapy Support
Current and Potential Future Innovations in Mental Health Care
Theoretical Incorporation of Psychedelic Treatment Into the US Payer Ecosystem
Visited 92 times, 1 Visit today